OSLO/LONDON, 8th June 2022: The Board of Directors of EXACT Therapeutics AS
("EXACT-Tx", "the Company" Euronext Growth: EXTX) has resolved on 8th June 2022
to increase the share capital of the Company by NOK 20.21 through the issuance
of 5,052 new shares. The new shares are issued pursuant to the authorisation
provided to the Board of Directors at the Annual General Meeting held in June,
2021, for the purpose of issuing shares under the Company's restricted stock
unit (RSU) program to its Board Members. The shares are issued at a price of NOK
19.00 per share, which equals the volume weighted average price of shares traded
in the ten trading days before the AGM on 8th June, 2022. Following the share
capital increase, the Company will have a share capital of NOK 119,988.88
divided into 29,997,219 shares, each with a nominal value of NOK 0.004. 

DISCLOSURE REGULATION This information is subject to the disclosure requirements
pursuant to Section 5-12 of the Norwegian Securities Trading Act.

ENDS
For more information, please contact:

Per Walday, CEO
EXACT Therapeutics
Email per.walday@exact-tx.com

Dominic Moreland, CFO 
EXACT Therapeutics 
Email: Dominic@exact-tx.com

About EXACT-Tx
EXACT-Tx is a Norwegian clinical-stage precision health company developing a
technology platform for targeted therapeutic enhancement - Acoustic Cluster
Therapy (ACT®). ACT® is a proprietary formulation of microclusters (PS101)
activated by ultrasound for enhanced drug targeting deployed in multiple
indications to enhance the therapeutic efficacy of medicines through the use of
ultrasound-mediated drug delivery, for patients across multiple diseases.
www.exact-tx.com

Forward looking statements
This announcement and any materials distributed in connection with this
announcement may contain certain forward-looking statements. By their nature,
forward-looking statements involve risk and uncertainty because they reflect the
Company's current expectations and assumptions as to future events and
circumstances that may not prove accurate. A number of material factors could
cause actual results and developments to differ materially from those expressed
or implied by this forward-looking statement.